These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34791637)

  • 1. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer.
    Lee SH; Hwang HK; Lee WJ; Kang CM
    Cell Oncol (Dordr); 2021 Dec; 44(6):1363-1371. PubMed ID: 34791637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
    Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
    Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
    Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
    World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.
    Baek G; Tse YF; Hu Z; Cox D; Buboltz N; McCue P; Yeo CJ; White MA; DeBerardinis RJ; Knudsen ES; Witkiewicz AK
    Cell Rep; 2014 Dec; 9(6):2233-49. PubMed ID: 25497091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
    Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
    Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Ferroptosis Signature in Overall Survival and Chemotherapy of Pancreatic Adenocarcinoma.
    Wei W; Hu Q; Li W; Li M; Dong S; Peng Y; Yin J; Lu Y; Liu L; Zhao Q
    DNA Cell Biol; 2022 Feb; 41(2):116-127. PubMed ID: 34898275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Berberine diminishes side population and down-regulates stem cell-associated genes in the pancreatic cancer cell lines PANC-1 and MIA PaCa-2.
    Park SH; Sung JH; Chung N
    Mol Cell Biochem; 2014 Sep; 394(1-2):209-15. PubMed ID: 24894821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
    Gordon ER; Wright CA; James M; Cooper SJ
    BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
    Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells.
    Pan Y; He B; Song G; Bao Q; Tang Z; Tian F; Wang S
    Oncol Rep; 2012 Jun; 27(6):2003-9. PubMed ID: 22427101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
    Ishida M; Sunamura M; Furukawa T; Akada M; Fujimura H; Shibuya E; Egawa S; Unno M; Horii A
    World J Gastroenterol; 2007 Sep; 13(34):4593-7. PubMed ID: 17729412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma.
    Fisel P; Stühler V; Bedke J; Winter S; Rausch S; Hennenlotter J; Nies AT; Stenzl A; Scharpf M; Fend F; Kruck S; Schwab M; Schaeffeler E
    Oncotarget; 2015 Oct; 6(31):30615-27. PubMed ID: 26384346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
    Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival.
    Baenke F; Dubuis S; Brault C; Weigelt B; Dankworth B; Griffiths B; Jiang M; Mackay A; Saunders B; Spencer-Dene B; Ros S; Stamp G; Reis-Filho JS; Howell M; Zamboni N; Schulze A
    J Pathol; 2015 Oct; 237(2):152-65. PubMed ID: 25965974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.
    Duong HQ; Yi YW; Kang HJ; Bae I; Jang YJ; Kwak SJ; Seong YS
    Int J Oncol; 2014 Jun; 44(6):2132-8. PubMed ID: 24676703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.